REG - Oncimmune Hldngs PLC - Total Voting Rights

Oncimmune HoldingsAnnouncement

04/05/2021 12:25

RNS Number : 4837X
  
Oncimmune Holdings PLC
  
04 May 2021
  
 

4 May 2021
 
 
Oncimmune Holdings plc
 
("Oncimmune" or the "Company")
 
Total Voting Rights
 
 
In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6), Oncimmune makes the following disclosure with respect to the share capital and voting rights of the Company.
 
Pursuant to the Company's existing block admission, and following the exercise of options over 17,927 ordinary shares in aggregate during April 2021 by current and former employees, as at 30 April 2021, the Company's issued share capital was 69,115,467 ordinary shares of £0.01 each with voting rights. The Company does not hold any shares in treasury.
 
The above figure of 69,115,467 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
 
 
For further information:
 
Oncimmune Holdings plc
Ron Kirschner, Company Secretary
contact@oncimmune.co.uk
 
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, James Hornigold
+44 (0)20 3829 5000
 
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin
+44 (0)20 7496 3000
 
WG Partners (Joint Broker)
David Wilson, Claes Spång
+44 (0)203 705 9321
 
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
TVREAFSLEAAFEFA